Maravai LifeSciences Holdings, Inc.
MRVI
$2.46
$0.072.93%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 47.40M | 46.85M | 56.41M | 65.20M | 69.42M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 47.40M | 46.85M | 56.41M | 65.20M | 69.42M |
| Cost of Revenue | 39.63M | 39.13M | 37.44M | 36.83M | 38.58M |
| Gross Profit | 7.77M | 7.73M | 18.96M | 28.37M | 30.84M |
| SG&A Expenses | 38.58M | 39.56M | 41.24M | 39.09M | 40.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.09M | 83.58M | 83.25M | 80.26M | 84.06M |
| Operating Income | -35.69M | -36.73M | -26.84M | -15.06M | -14.64M |
| Income Before Tax | -74.13M | -52.69M | -46.50M | -175.64M | -20.86M |
| Income Tax Expenses | -4.29M | 162.00K | -7.00K | 311.00K | -2.44M |
| Earnings from Continuing Operations | -69.84M | -52.85M | -46.50M | -175.96M | -18.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 30.25M | 22.91M | 20.35M | 76.92M | 8.63M |
| Net Income | -39.59M | -29.95M | -26.15M | -99.04M | -9.79M |
| EBIT | -35.69M | -36.73M | -26.84M | -15.06M | -14.64M |
| EBITDA | -22.53M | -24.00M | -14.47M | -3.12M | -2.21M |
| EPS Basic | -0.27 | -0.21 | -0.18 | -0.70 | -0.07 |
| Normalized Basic EPS | 0.02 | -0.02 | 0.00 | 0.45 | -0.04 |
| EPS Diluted | -0.27 | -0.21 | -0.18 | -0.70 | -0.07 |
| Normalized Diluted EPS | 0.02 | -0.02 | 0.00 | 0.45 | -0.04 |
| Average Basic Shares Outstanding | 144.24M | 143.43M | 141.81M | 141.56M | 135.84M |
| Average Diluted Shares Outstanding | 144.24M | 143.43M | 141.81M | 141.56M | 135.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |